cover
Contact Name
-
Contact Email
-
Phone
-
Journal Mail Official
respirasi@journal.unair.ac.id
Editorial Address
Jl. Mayjen Prof. Dr. Moestopo 6-8 Surabaya 60286 Indonesia
Location
Kota surabaya,
Jawa timur
INDONESIA
Jurnal Respirasi (JR)
Published by Universitas Airlangga
ISSN : 24070831     EISSN : 26218372     DOI : -
Core Subject : Health,
Jurnal Respirasi is a National journal in accreditation process managed by Department of Pulmonology & Respiratory Medicine Faculty of Medicine Airlangga University - Dr. Soetomo General Hospital, Surabaya. Publish every January, May, September every year with each of 5 (five) complete texts in Indonesian.
Arjuna Subject : -
Articles 7 Documents
Search results for , issue "Vol. 5 No. 2 (2019): Mei 2019" : 7 Documents clear
Drug Induced Hepatitis pada Tuberkulosis Paru dengan Multisite Tuberkulosis Ekstraparu : [Drug-Induced Hepatitis in Mixed Pulmonary and Extrapulmonary Tuberculosis] Made Agustya Darma Putra Wesnawa; Tutik Kusmiati
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (390.862 KB) | DOI: 10.20473/jr.v5-I.2.2019.34-40

Abstract

Background: Tuberculosis (TB) continues to be a major health problem in developing country. Lung is the most common site for Mycobacterium tuberculosis (MTB) infection, but dissemination may occur to any part of the body resulting in extrapulmonary TB. Hepatotoxicity is one of the most frequent adverse events that occur during TB treatment. Case: A 35-year-old female patient came with cough, dyspnea, fever, abdominal pain, history of mass in right inguinal lymph node, and malnutrition. Histopathology from excisional biopsy of inguinal lymph node showed granulomatous inflammation. Computed tomography of abdomen showed intraabdominal TB. Chest X-ray showed right pleural effusion, with exudate pleural fluid and mononuclear dominant. After 1 week consuming antituberculous drug, patient got nausea and vommiting, increased of ALT and AST, total and direct bilirubin. Antituberculous drug was stopped and switched to levofloxacin, ethambutol, and streptomycin. After clinical improvement and liver function return to normal, desensitization of rifampicin and isoniazide was started. Desensitization started with rifampicin for three days, and followed with isoniazide for three days. In total, the patient got rifampicin, isoniazide, and ethambutol for 9 months. Evaluation of treatments are clinical improvement and weight gain. Acid fast baccili sputum was negatif, no pleural effusion on chest X-ray, and normal abdominal ultrasound. Conclusion: MTB can spread to other organs which cause multisite extrapulmonary TB. Side effect can occur during TB treament, and this is not the reason to stop the therapy. Individual ATD therapy shows good response in this case.
Back Matter Vol 5 No 2, 2019 Back Matter
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (185.531 KB) | DOI: 10.20473/jr.v5-I.2.2019.%p

Abstract

Peran Steroid pada Pneumocystis Pneumonia Ditinjau Berdasarkan Imunopatogenesis : [Immunopathogenesis of Steroid in Pneumocystis Pneumonia] Resti Yudhawati; Whendy Wijaksono
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (668.45 KB) | DOI: 10.20473/jr.v5-I.2.2019.57-64

Abstract

Pneumocystis Pneumonia (PCP) is a potentially life-threatening infection that can occur in individuals who are immunocompromised. In PCP steroid use is still recommended especially in patients with moderate and severe severity. Corticosteroids are given along with anti-pneumocystis therapy and are known to reduce the incidence of mortality and respiratory failure associated with PCP. Innate immunity and adaptive immunity are symbiotic relationships to provide optimal defense for the lungs and other organs and tissues from infection PCP. The corticosteroid mechanism in PCP is based on an anti-inflammatory mechanism especially its role in inhibiting neutrophils. Many clinicians believe the administration of anti-pneumocystis causes the acceleration of inflammation. Because the inflammatory process increases when anti-pneumocystis therapy is started, corticosteroid therapy is useful before inflammation occurs which causes extensive damage to the lungs.
Perbaikan Kualitas Hidup pada Pasien Solitary Fibrous Tumor Mediastinum: Perspektif Kemoterapi Paliatif: [Improvement of Quality of Life in Mediastinal Solitary Fibrous Tumor: Paliative Chemoteraphy Perspective] Aryo Dirgantara Putra; Winarinani Koesoemoprodjo
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (637.408 KB) | DOI: 10.20473/jr.v5-I.2.2019.41-46

Abstract

Background: Mediastinal solitary fibrous tumor (SFT) is a rare spindle cell neoplasm. Approximately 1 to 8% of these intrathoracic tumors have been reported to occur in the mediastinum. The chief complaints of mediastinal SFT are cough, shortness of breath or chest pain, or may occur as asymptomatic incidental mass. The treatment of choice for SFT is extensive surgical resection. However, when the tumor cannot be removed surgically or when metastases occur, chemotherapy and or radiotherapy can be proposed as palliative treatments. Case: A 19-year-old man with chief complaint of left chest pain and referred to his left back. The complaint is accompanied by cough without sputum and hoarseness. In thoracic CT scan with contrast, we found giant cystic mass suspect malignancy around 17x12x18 cm in left hemithorax, a minimal pericardial effusion, and left pleural effusion. There were positive tumor cell cytoplasm results in vimentin, negative tumor cell cytoplasm in CK, positive tumor cell membrane in CD99, cytoplasm of focal positive tumor cells in EMA, and negative tumor cells in CD34 which supported a solitary fibrous tumor in the immunohistochemical staining analysis. Doxorubicin-Ifosfamide regimen was the choice of chemotherapy palliative treatment in the case report. In the CT scan evaluation of thorax with contrast, we found stable disease (RECIST criteria) with improve quality of life (QOL) according to EQ-5D-3L, 11111 indicated no problems in 5 dimensions, such as mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Conclusion: Mediastinal SFT is a rare spindle cell neoplasm, and the diagnosis requires pathological and immunohistochemical staining analysis. Doxorubicin-Ifosfamide regimen can be proposed as a palliative chemotherapy regimen, which has been shown to improve QOL patients in Mediastinal SFT. EQ-5D is a simple tool that can be used to measure QOL such as mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.
Penggunaan Extrafine Beclometason Diproprionat/Formoterol Fumarat pada PPOK : [Combined Extrafine Beclomethason Diproprionat/Formoteral Fumarat in COPD] Sakinatus Syarifah; Muhammad Amin
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (587.68 KB) | DOI: 10.20473/jr.v5-I.2.2019.47-56

Abstract

Chronic obstructive pulmonary disease (COPD) is a condition characterised by poorly reversible airflow limitation that is generally progressive and causes serious disability. Exacerbations and co-morbidities contribute to the overall severity in individual patients. A fixed-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination of extrafine beclometasone dipropionate and formoterol fumarate (BDP/FF) has been recently approved for use in COPD. Small airway inflammation and remodelling are cardinal features of COPD; therefore, the ability of this extrafine formulation to reach the small, as well as the large, airways is likely to be therapeutically important by enabling treatment of inflammatory processes in the whole bronchial tree. The clinical development of extrafine BDP/FF has demonstrated significant benefits over extrafine FF in terms of lung function improvement and reduction of the exacerbation rate, thus supporting the beneficial effect of an ICS combined to a LABA in COPD patients. Head-to-head comparison studies versus other ICS/LABA combinations have shown that extrafine formulation enables clinical benefits to be achieved with a lower dose of ICS. Extrafine BDP/FF showed lung function and dyspneea improvements comparable to other ICS/LABAs, and a significantly faster onset of action was observed when compared with a salmeterol-containing fixed-dose combination.
Front Matter Vol 5 No 2, 2019 Front Matter
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (146.042 KB) | DOI: 10.20473/jr.v5-I.2.2019.%p

Abstract

Perbandingan Pola Kuman dan Kadar Biomarker Inflamasi Penderita Severe Pneumonia dengan Penderita Non-severe Pneumonia : [Bacterial Pattern and Inflammatory Biomarker in Severe Pneumonia Compared to Non-Severe Pneumonia Patient] Daniel Maranatha; Mawardi Mawardi
Jurnal Respirasi Vol. 5 No. 2 (2019): Mei 2019
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (232.811 KB) | DOI: 10.20473/jr.v5-I.2.2019.29-33

Abstract

Background: Severe pneumonia is still a serious problem with high mortality rate. The cause of severe pneumonia due to high inflammation or different microbial pattern compared to non-severe pneumonia is still unknown. Methods: An analytic observational study with cross-sectional design was performed in patients with severe pneumonia and non-severe pneumonia treated in intensive care unit (ICU), intensive observation room (ROI), and all inpatient wards of Dr. Soetomo General Hospital Surabaya for a period of 1 year from September 2017 to September 2018. Patients with pneumonia accompanied by active pulmonary tuberculosis (TB), lung tumors, and acute infections other than pulmonary organs were excluded from this study. All study subjects were taken for sputum samples for aerobic sputum culture and blood samples for biomarker examination of C-reactive protein (CRP) and procalcitonin (PCT). Results: The total subjects were 64. Mean value of CRP and PCT levels severe pneumonia was 143.8 mg/L and PCT levels 23.1 ng/ml, respectively. Mean value of CRP and PCT levels non-severe pneumonia was 75.0 mg/L and PCT level 8.08 ng/ml, respectively. There was a significant difference in CRP and PCT levels of severe pneumonia and non-severe pneumonia patients (p < 0.05), whereas no meaningful difference in microbial patterns in both groups. Conclusion: Since inflammation responses of severe pneumonia were more massive than nonsevere patients, it will produce higher CRP and PCT levels.

Page 1 of 1 | Total Record : 7